‘Killed it on the spot': Infant bites cobra to death after it coiled around his hands
The one-year-old boy, identified only by his first name Govinda, bit the cobra while he was playing at his home in the small town of Bettiah near the Indo-Nepal border, according to local news reports.
"When we saw the snake in the child's hand, everyone rushed towards him, but in the meantime, he already bit the snake, killing it on the spot," the child's grandmother told local news.
After biting the snake, the boy fainted and was rushed to a primary health care centre for initial treatment, after which he was taken to the town's Government Medical College Hospital (GMCH).
'The boy, Govind Kumar, was referred here yesterday by the primary health centre close to his village where he was rushed by family members after he fainted soon after chewing on the live snake,' hospital superintendent Duvakant Mishra told Indian Express.
The venom's effects were reportedly mild, only knocking the boy unconscious, but not fatal.
"Timely treatment saved Govinda's life," Saurabh Kumar, a doctor of the government hospital, told the Times of India.
"The child's condition is currently stable and treatment is being administered under the supervision of doctors. The medical team is treating the child, providing continuous medication, and he is under observation,' Dr Kumar said.
Govinda reportedly is being closely monitored at GMCH Bettiah with treatment for poisoning expected to start if he started showing any symptoms, according to local news reports.
India has around 300 species of snakes, including 60 highly venomous snakes such as the Russell's vipers, kraits, and the saw-scaled viper, which are responsible for most of the bite-related deaths.
The Indian cobra completes this list of the "big four" species responsible for the most snakebites in India.
The country recorded over a million snake bite deaths in just two decades from 2000-19, according to a study published in 2020 in the journal eLife.
More than two-thirds of the recorded deaths came from eight of India's 28 states, including Bihar, Jharkhand, Madhya Pradesh, Odisha and Uttar Pradesh.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
8 hours ago
- Yahoo
Human Papilloma Virus Testing Market Research Report 2025-2033 Featuring Abbott Laboratories, BioMerieux, Bio-Rad Laboratories, Epigenomics, Siemens Healthineers, Hologic, Qiagen, F. Hoffmann-La Roche
The Human Papillomavirus (HPV) Testing Market is projected to grow from USD 1.52 billion in 2024 to USD 3.62 billion by 2033, at a 10.11% CAGR from 2025. This growth is fueled by increased cervical cancer awareness, robust screening programs, and advancements in diagnostic technologies. HPV, a significant sexually transmitted infection, plays a critical role in cervical and other cancers, highlighting the importance of early detection through testing. Global initiatives, especially in developed nations, have embraced HPV-based screenings, driving demand. However, challenges such as limited access and high technology costs in low-income countries remain. Notable market segments include consumables, immunodiagnostics, and PCR testing. Key regions like the U.S., France, India, and Saudi Arabia see varied growth based on governmental support, awareness, and infrastructure. Human Papilloma Virus Testing Market Dublin, July 29, 2025 (GLOBE NEWSWIRE) -- The "Human Papilloma Virus Testing Market Size and Share Analysis - Growth Trends and Forecast Report 2025-2033" report has been added to Human papillomavirus (HPV) Testing Market was USD 1.52 billion in 2024 and is expected to reach USD 3.62 billion by 2033, with a CAGR of 10.11% from 2025 to 2033. The growth is due to increasing awareness of cervical cancer, increased screening programs, and technological advancements in diagnostic technologies in global healthcare systems. Internationally, the use of HPV testing is increasing with growing awareness regarding prevention of cervical cancer, government-sponsored screening programs, and WHO's initiative to eliminate cervical cancer as a public health issue. Developed countries have embraced HPV-based screening on a large scale, and developing nations are also adopting it, with the support of global health programs. Its high sensitivity and long-term risk prediction make it a method of choice in contemporary gynecological Driver in the Human Papilloma Virus (HPV) Testing Market Increasing Awareness and Government Screening ProgramsInternational awareness programs and country-level screening programs have increased demand for HPV testing to a large extent. Governments in developed and emerging economies are adopting routine cervical cancer screening guidelines for women aged 30 and older. WHO organizations advocate for HPV testing as a key tool for early detection of cancer. Greater awareness of HPV-associated cancers and immunization also reinforces demand. These efforts account for early diagnosis, prompt intervention, and overall reduction in HPV-associated disease burden, thus driving the market forward. SEP 2024, The United States, Australia, India, and Japan are rolling out a key initiative to fight cervical cancer across the Indo-Pacific, a preventable disease which is a significant health crisis in the region. This initiative is part of larger announcements made during the Quad Leaders Breakthroughs in HPV TestingInnovation in diagnostic methods - like PCR, next-generation sequencing, and self-sampling kits - has revolutionized HPV testing by enhancing accuracy, accessibility, and convenience. Automated platforms, multiplex assays, and liquid-based cytology enable quicker turnaround times and large-scale screening. These technologies are particularly precious in resource-poor settings and enable wider adoption in public health systems. Ongoing R&D spending by diagnostic firms serves to improve test sensitivity and affordability, fueling additional market growth. June 2023, The WHO has prequalified a fourth test for human papillomavirus (HPV). Although most HPV infections will clear on their own, a few of the higher-risk types can cause cervical cancer, so HPV testing is important for cervical cancer Prevalence of HPV-Associated Cancers Growing global incidence of HPV-related cancers, particularly cervical cancer, is a strong market driver. Cervical cancer is the fourth leading female cancer in the world according to the WHO, and the overwhelming majority of cases are caused by high-risk HPV types. Growing cases of cancer have driven the need for early detection strategies, putting HPV testing at the center of preventive medicine. As healthcare professionals and patients strive for surefire diagnostic measures, HPV testing is also becoming a necessity in women's health care. An estimated 47,984 new cases of cancer occur each year in the United States in areas of the body where human papillomavirus (HPV) commonly in the Human Papilloma Virus (HPV) Testing Market Limited Access in Low-Income CountriesIn spite of worldwide awareness, HPV testing is not readily available in low- and middle-income countries because of a lack of healthcare infrastructure and resources. There are few laboratory facilities, skilled professionals, and regular screening programs in most areas. Cultural taboo and sexual stigma also discourage HPV testing participation. This inequality avoids early diagnosis and enhances the risk of cervical cancer at advanced stages. It is essential to overcome these barriers using cost-effective point-of-care diagnostics and education initiatives for equitable market Cost of Sophisticated HPV Testing TechnologiesThe price of advanced HPV testing technologies, including PCR-based platforms and DNA sequencing, can be out of reach for healthcare systems and some patients. As developed nations implement these technologies into regular screening, the affordability gap restricts accessibility in resource-scarce settings. In addition, maintenance costs, quality assurance, and specialized staff requirements contribute to higher operating costs for clinics and laboratories. This cost factor hinders mass screening activities, particularly in developing countries. Key Players Analyzed: Overview, Key Persons, Recent Development & Strategies, Financial Insights Abbott Laboratories BioMerieux SA Bio-Rad Laboratories, Inc. Epigenomics AG Siemens Healthineers AG Hologic Inc Qiagen NV F. Hoffmann-La Roche Ltd Key Attributes: Report Attribute Details No. of Pages 200 Forecast Period 2024 - 2033 Estimated Market Value (USD) in 2024 $1.52 Billion Forecasted Market Value (USD) by 2033 $3.62 Billion Compound Annual Growth Rate 10.1% Regions Covered Global Key Topics Covered: 1. Introduction2. Research Methodology2.1 Data Source2.1.1 Primary Sources2.1.2 Secondary Sources2.2 Research Approach2.2.1 Top-Down Approach2.2.2 Bottom-Up Approach2.3 Forecast Projection Methodology3. Executive Summary4. Market Dynamics4.1 Growth Drivers4.2 Challenges5. Human Papilloma Virus Testing Market5.1 Historical Market Trends5.2 Market Forecast6. Human Papilloma Virus Testing Market Share Analysis6.1 By Application6.2 By Product6.3 By Technology6.4 By End Use6.5 By Countries7. Application7.1 Cervical Cancer Screening7.2 Vaginal Cancer Screening8. Product8.1 Consumables8.2 Instruments8.3 Services9. Technology9.1 Polymerase chain reaction (PCR)9.2 Liquid-based cytology9.3 Immunodiagnostics9.4 Hybrid Capture9.5 Others10. End Use10.1 Hospitals & Clinics10.2 Laboratories10.3 Others11. Countries11.1 North America11.1.1 United States11.1.2 Canada11.2 Europe11.2.1 France11.2.2 Germany11.2.3 Italy11.2.4 Spain11.2.5 United Kingdom11.2.6 Belgium11.2.7 Netherlands11.2.8 Turkey11.3 Asia-Pacific11.3.1 China11.3.2 Japan11.3.3 India11.3.4 South Korea11.3.5 Thailand11.3.6 Malaysia11.3.7 Indonesia11.3.8 Australia11.3.9 New Zealand11.4 Latin America11.4.1 Brazil11.4.2 Mexico11.4.3 Argentina11.5 Middle East & Africa11.5.1 Saudi Arabia11.5.2 UAE11.5.3 South Africa12. Porter's Five Forces Analysis12.1 Bargaining Power of Buyers12.2 Bargaining Power of Suppliers12.3 Degree of Rivalry12.4 Threat of New Entrants12.5 Threat of Substitutes13. SWOT Analysis13.1 Strength13.2 Weakness13.3 Opportunity13.4 Threat 14. Key Players Analysis For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Human Papilloma Virus Testing Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
9 hours ago
- Yahoo
Human Papilloma Virus Testing Market Research Report 2025-2033 Featuring Abbott Laboratories, BioMerieux, Bio-Rad Laboratories, Epigenomics, Siemens Healthineers, Hologic, Qiagen, F. Hoffmann-La Roche
The Human Papillomavirus (HPV) Testing Market is projected to grow from USD 1.52 billion in 2024 to USD 3.62 billion by 2033, at a 10.11% CAGR from 2025. This growth is fueled by increased cervical cancer awareness, robust screening programs, and advancements in diagnostic technologies. HPV, a significant sexually transmitted infection, plays a critical role in cervical and other cancers, highlighting the importance of early detection through testing. Global initiatives, especially in developed nations, have embraced HPV-based screenings, driving demand. However, challenges such as limited access and high technology costs in low-income countries remain. Notable market segments include consumables, immunodiagnostics, and PCR testing. Key regions like the U.S., France, India, and Saudi Arabia see varied growth based on governmental support, awareness, and infrastructure. Human Papilloma Virus Testing Market Dublin, July 29, 2025 (GLOBE NEWSWIRE) -- The "Human Papilloma Virus Testing Market Size and Share Analysis - Growth Trends and Forecast Report 2025-2033" report has been added to Human papillomavirus (HPV) Testing Market was USD 1.52 billion in 2024 and is expected to reach USD 3.62 billion by 2033, with a CAGR of 10.11% from 2025 to 2033. The growth is due to increasing awareness of cervical cancer, increased screening programs, and technological advancements in diagnostic technologies in global healthcare systems. Internationally, the use of HPV testing is increasing with growing awareness regarding prevention of cervical cancer, government-sponsored screening programs, and WHO's initiative to eliminate cervical cancer as a public health issue. Developed countries have embraced HPV-based screening on a large scale, and developing nations are also adopting it, with the support of global health programs. Its high sensitivity and long-term risk prediction make it a method of choice in contemporary gynecological Driver in the Human Papilloma Virus (HPV) Testing Market Increasing Awareness and Government Screening ProgramsInternational awareness programs and country-level screening programs have increased demand for HPV testing to a large extent. Governments in developed and emerging economies are adopting routine cervical cancer screening guidelines for women aged 30 and older. WHO organizations advocate for HPV testing as a key tool for early detection of cancer. Greater awareness of HPV-associated cancers and immunization also reinforces demand. These efforts account for early diagnosis, prompt intervention, and overall reduction in HPV-associated disease burden, thus driving the market forward. SEP 2024, The United States, Australia, India, and Japan are rolling out a key initiative to fight cervical cancer across the Indo-Pacific, a preventable disease which is a significant health crisis in the region. This initiative is part of larger announcements made during the Quad Leaders Breakthroughs in HPV TestingInnovation in diagnostic methods - like PCR, next-generation sequencing, and self-sampling kits - has revolutionized HPV testing by enhancing accuracy, accessibility, and convenience. Automated platforms, multiplex assays, and liquid-based cytology enable quicker turnaround times and large-scale screening. These technologies are particularly precious in resource-poor settings and enable wider adoption in public health systems. Ongoing R&D spending by diagnostic firms serves to improve test sensitivity and affordability, fueling additional market growth. June 2023, The WHO has prequalified a fourth test for human papillomavirus (HPV). Although most HPV infections will clear on their own, a few of the higher-risk types can cause cervical cancer, so HPV testing is important for cervical cancer Prevalence of HPV-Associated Cancers Growing global incidence of HPV-related cancers, particularly cervical cancer, is a strong market driver. Cervical cancer is the fourth leading female cancer in the world according to the WHO, and the overwhelming majority of cases are caused by high-risk HPV types. Growing cases of cancer have driven the need for early detection strategies, putting HPV testing at the center of preventive medicine. As healthcare professionals and patients strive for surefire diagnostic measures, HPV testing is also becoming a necessity in women's health care. An estimated 47,984 new cases of cancer occur each year in the United States in areas of the body where human papillomavirus (HPV) commonly in the Human Papilloma Virus (HPV) Testing Market Limited Access in Low-Income CountriesIn spite of worldwide awareness, HPV testing is not readily available in low- and middle-income countries because of a lack of healthcare infrastructure and resources. There are few laboratory facilities, skilled professionals, and regular screening programs in most areas. Cultural taboo and sexual stigma also discourage HPV testing participation. This inequality avoids early diagnosis and enhances the risk of cervical cancer at advanced stages. It is essential to overcome these barriers using cost-effective point-of-care diagnostics and education initiatives for equitable market Cost of Sophisticated HPV Testing TechnologiesThe price of advanced HPV testing technologies, including PCR-based platforms and DNA sequencing, can be out of reach for healthcare systems and some patients. As developed nations implement these technologies into regular screening, the affordability gap restricts accessibility in resource-scarce settings. In addition, maintenance costs, quality assurance, and specialized staff requirements contribute to higher operating costs for clinics and laboratories. This cost factor hinders mass screening activities, particularly in developing countries. Key Players Analyzed: Overview, Key Persons, Recent Development & Strategies, Financial Insights Abbott Laboratories BioMerieux SA Bio-Rad Laboratories, Inc. Epigenomics AG Siemens Healthineers AG Hologic Inc Qiagen NV F. Hoffmann-La Roche Ltd Key Attributes: Report Attribute Details No. of Pages 200 Forecast Period 2024 - 2033 Estimated Market Value (USD) in 2024 $1.52 Billion Forecasted Market Value (USD) by 2033 $3.62 Billion Compound Annual Growth Rate 10.1% Regions Covered Global Key Topics Covered: 1. Introduction2. Research Methodology2.1 Data Source2.1.1 Primary Sources2.1.2 Secondary Sources2.2 Research Approach2.2.1 Top-Down Approach2.2.2 Bottom-Up Approach2.3 Forecast Projection Methodology3. Executive Summary4. Market Dynamics4.1 Growth Drivers4.2 Challenges5. Human Papilloma Virus Testing Market5.1 Historical Market Trends5.2 Market Forecast6. Human Papilloma Virus Testing Market Share Analysis6.1 By Application6.2 By Product6.3 By Technology6.4 By End Use6.5 By Countries7. Application7.1 Cervical Cancer Screening7.2 Vaginal Cancer Screening8. Product8.1 Consumables8.2 Instruments8.3 Services9. Technology9.1 Polymerase chain reaction (PCR)9.2 Liquid-based cytology9.3 Immunodiagnostics9.4 Hybrid Capture9.5 Others10. End Use10.1 Hospitals & Clinics10.2 Laboratories10.3 Others11. Countries11.1 North America11.1.1 United States11.1.2 Canada11.2 Europe11.2.1 France11.2.2 Germany11.2.3 Italy11.2.4 Spain11.2.5 United Kingdom11.2.6 Belgium11.2.7 Netherlands11.2.8 Turkey11.3 Asia-Pacific11.3.1 China11.3.2 Japan11.3.3 India11.3.4 South Korea11.3.5 Thailand11.3.6 Malaysia11.3.7 Indonesia11.3.8 Australia11.3.9 New Zealand11.4 Latin America11.4.1 Brazil11.4.2 Mexico11.4.3 Argentina11.5 Middle East & Africa11.5.1 Saudi Arabia11.5.2 UAE11.5.3 South Africa12. Porter's Five Forces Analysis12.1 Bargaining Power of Buyers12.2 Bargaining Power of Suppliers12.3 Degree of Rivalry12.4 Threat of New Entrants12.5 Threat of Substitutes13. SWOT Analysis13.1 Strength13.2 Weakness13.3 Opportunity13.4 Threat 14. Key Players Analysis For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Human Papilloma Virus Testing Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Melden Sie sich an, um Ihr Portfolio aufzurufen.
Yahoo
9 hours ago
- Yahoo
Family's plea after 2yo girl's tragic death
A Perth family has issued an emotional plea after their two-year-old daughter died from the flu. In a letter shared by the Immunisation Foundation of Australia, the heartbroken family described how the health of their two-year-old daughter, Aabi, rapidly deteriorated from the virus. Only a few months away from turning three, Aabi and her family had returned to their home in Perth on April 30 after spending a month abroad in India visiting relatives. Aabi's parents said she was 'reluctant' to return to daycare, but was sent back the next day. It was only a few days later that Aabi vomited after eating her regular banana and milk. 'I initially thought it was due to her energetic play with her sister,' her mother wrote. 'As I cleaned her, I noticed she felt lukewarm.' The two-year-old complained of a headache, with her mother giving her a dose of paracetamol syrup and a 'gentle forehead massage' that seemed to help. While Aabi's mood seemed to improve, her fever - and the niggling headache - returned a short time later. '(On) Sunday, May 4th, she woke as usual - enjoying two biscuits with my tea, her milk, and then a banana,' her mother wrote. 'She was playing, singing, and seemed well. 'Relieved, I started my regular Sunday household tasks while the girls entertained themselves.' However by about 11am that morning, Aabi's temperature was rising again and her headache had returned. 'I sat beside her, waiting for the fever to drop, but it kept climbing,' her mother wrote. Aabi's fever kept climbing to 40.6C and she was rushed to hospital, where her dehydration made it difficult for doctors to figure out the problem. 'It felt like she deteriorated significantly and too quickly,' her mother said. Aabi had a 'gentle seizure' while in hospital and was later diagnosed with influenza. 'The decision was made to perform a CT scan and then transfer her to the ICU, as she was highly febrile and partially unconscious,' the letter read. However, the little girl's health had deteriorated too quickly for the CT scan to be effective and she instead required an MRI scan. Aabi's mum said it was then she believed they had lost their little girl, saying her pupils were non-responsive and 'she was beyond anyone's help'. In the span of a few days, Aabi had gone from being a 'healthy, happy, active, and fun-loving child' to lying unconscious in the hospital bed. The MRI scan confirmed the worst. 'The MRI confirmed total brain death due to acute necrotising encephalitis, a devastating complication of the influenza infection,' her mother wrote. 'The virus's rapid progression with such minimal initial symptoms – just a normal fever and headache, which so many children her age experience regularly – gave us no indication of the extreme seriousness of the situation.' Aabi's mother said doctors suspect her daughter's immune system reacted 'much more aggressively than usual', which led to 'acute inflammation and severe damage to her brain'. 'We lost our beautiful Aabi at the hands of what seemed like a 'mere virus',' she said. 'Aabi will forever be two years and nine months old,' her mother wrote, describing her daughter as the 'radiant joy of our lives and the very heart of our home'. Flu spike 'really concerning' Immunisation Foundation of Australia founder Catherine Hughes said Aabi's story was a reminder of the tragic impact influenza can have, and highlights just how vulnerable young children are to infectious diseases. She said an ongoing spread of misinformation was leading to shockingly low rates of flu vaccination, something she described as a 'serious public health concern'. According to figures from the National Centre for Immunisation Research and Surveillance (NCRIS), more than 230,000 lab-confirmed flu cases have been reported in the country as of late July. Less than a quarter of those cases are children under the age of five. Ms Hughes said the numbers were 'really concerning'. 'Many of us might mistakenly think of the flu as 'just a bad cold', especially after a mild case,' she told NewsWire. 'However, influenza can be extremely severe, leading to serious complications, hospitalisation, and death, even for healthy children and adults.' This could be reduced with higher vaccination rates, she said. 'We urge families to prioritise vaccination as a proactive step to protect their children, prevent the wider spread of the virus, and ultimately, help protect all Australians,' she told NewsWire. Monash University Epidemiological Modelling Unit for the School of Public Health and Preventive Medicine associate professor James Trauer reiterated it was important for Australians to get vaccinated against the flu. He told NewsWire the flu vaccine presented 'little chemicals to the immune system' that are in both the vaccine and flu virus, meaning the body is exposed to the chemicals without the body having to be exposed to the flu virus itself. 'So you develop antibodies … once you've got those antibodies, you have a more effective, more rapid response to the vaccine,' he said. He said children under five and the population over 65 were the biggest priority for flu vaccinations, though the general public - particularly those with young children - should also get the jab. 'The flu transmits a lot within family units,' he said. '(The) flu causes a major epidemic every winter, and people do die of it every year, and so it's important for us to do everything that we can (to prevent it).' While there are 'some other treatments' to prevent the virus, he said 'vaccination is really the best … preventive and effective intervention' that can 'really help us to reduce the flu each winter'.
